Zosano Pharma Corp
ZSAN
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-7,486,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.27 |
| Beta | 3.29 |
| Outstanding Shares | 4,248,000 |
Return
| Return on Equity | -393.64% |
|---|---|
| Return on Assets | -209.18% |
| Return on Invested Capital | -329.21% |
Valuation & Multiples
| P/E Ratio | -2.08 |
|---|---|
| PEG | -0.67 |
| Price to Sales | - |
| Price to Book Ratio | 0.19 |
| Enterprise Value to Revenue | -11.36 |
| Enterprise Value to EBIT | 0.14 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.81 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zosano Pharma Corp
45 employees
CEO: Steven Lo Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to pati...